MRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. Issue 4 (18th February 2022)

• Record Type: Journal Article
• Authors: McLean, Huong Q.; McClure, David L.; King, Jennifer P.; Meece, Jennifer K.; Pattinson, David; Neumann, Gabriele; Kawaoka, Yoshihiro; Rolfes, Melissa A.; Belongia, Edward A.
• Is Part Of: Influenza and other respiratory viruses. Volume 16:Issue 4(2022)
• Page Start: 607
• Page End: 612
• Publication Date: 2022-02-18
• Subjects: COVID‐19 -- SARS‐CoV‐2 -- vaccine effectiveness; Influenza -- Periodicals; Respiratory infections -- Periodicals; Virus diseases -- Periodicals; Influenza, Human -- Periodicals; Respiratory Tract Diseases -- Periodicals; Virus Diseases -- Periodicals; Grippe -- Périodiques; Appareil respiratoire -- Infections -- Périodiques; Maladies à virus -- Périodiques; 616.203
• DOI: 10.1111/irv.12970
• Languages: English
• ISSNs: 1750-2640

Abstract

Abstract: Reduced COVID‐19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS‐CoV‐2 Delta (B.1.617.2) variant. Two‐dose VE against laboratory‐confirmed SARS‐CoV‐2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time‐varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID‐19 vaccines overall, 65% for Moderna, and 50% for Pfizer‐BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID‐19 vaccines overall, 59% for Moderna, and 52% for Pfizer‐BioNTech.